Zobrazeno 1 - 10
of 409
pro vyhledávání: '"E M Veys"'
Autor:
Herman Mielants, Pieter Rottiers, M. De Vos, Erik Remaut, P Van Hummelen, C.A. Cuvelier, Harald Peeters, Dirk Elewaut, Bert Vander Cruyssen, F De Keyser, Debby Laukens, E M Veys, T Boonefaes, Lothar Steidler, K Knecht
Publikováno v:
Europe PubMed Central
Background: Intestinal inflammation is a common feature of spondyloarthropathy (SpA) and Crohn’s disease. Inflammation is manifested clinically in Crohn’s disease and subclinically in SpA. However, a fraction of patients with SpA develops overt C
Publikováno v:
Autoimmunity Reviews. 4:468-474
Anti-citrullinated protein/peptide antibodies (ACPA) are highly specific and sensitive markers for rheumatoid arthritis (RA). For instance, for the anti-CCP2 assay, sensitivities ranging from 55% to 80% and specificities ranging from 90% to 98% have
Autor:
Herman Mielants, Ilse Hoffman, M. De Vos, Erik Remaut, C.A. Cuvelier, F De Keyser, Debby Laukens, P Coucke, Harald Peeters, E M Veys, B. Vander Cruyssen, Denis Marichal
Publikováno v:
Clinical and Experimental Immunology. 140:354-359
Summary Carriage of CARD15 gene polymorphisms and the serological marker anti-Saccharomyces cerevisiae antibodies (ASCA) are two markers for Crohn's disease (CD). Similar phenotypes have been associated with both markers. In the present study we anal
Publikováno v:
International Journal of Immunopathology and Pharmacology. 17:107-115
Rheumatoid arthritis is a chronic inflammatory joint disease characterized by the presence of autoantibodies. The best known autoantibody is the rheumatoid factor. Another group of antibodies directed against citrullinated epitopes is proven to be mo
Autor:
Herman Mielants, E M Veys, N Van den Bossche, A Herssens, Dominique Baeten, F De Keyser, Elli Kruithof, F. Van den Bosch
Publikováno v:
Annals of the rheumatic diseases, 62(9), 829-834. BMJ Publishing Group
Background: Recent studies with infliximab indicate the therapeutic potential of tumour necrosis factor α blockade in spondyloarthropathy (SpA). Because defective host defence is implicated in the pathogenesis of SpA, the potential side effects of t
Publikováno v:
Annals of the Rheumatic Diseases. 61:1090-1094
Objective: To determine the diagnostic distribution in a consecutive anti-SSA and/or anti-SSB positive population. Methods: A total of 15 937 serum samples from 10 550 consecutive patients were analysed for antinuclear antibodies (ANAs) on HEp-2 cell
Autor:
D.L. Baeten, E M Veys, A Herssens, Elli Kruithof, F. Van den Bosch, Herman Mielants, F De Keyser
Publikováno v:
Annals of the rheumatic diseases, 61(3), 207-212. BMJ Publishing Group
Background: In a pilot study, the anti-tumour necrosis factor α monoclonal antibody, infliximab, induced a rapid and significant improvement in global, peripheral, and axial disease manifestations of patients with active spondyloarthropathy. Objecti
Publikováno v:
Osteoarthritis and Cartilage. 9:341-350
Aim To preserve viable, metabolically active chondrocytes cultured in alginate beads at −196°C for further use in in vitro and in vivo studies. Methods Human articular chondrocytes were isolated from femoral condyles within 24h post mortem. To opt
Publikováno v:
Clinical Rheumatology. 19:291-295
Anti-SSA/Ro antibodies are the most prevalent type of antinuclear antibody (ANA). Anti-SSA/ Ro-positive sera may recognise two proteins: a 52 kDa (Ro52) and a 60 kDa (Ro60) subunit. We studied the sensitivity for Ro60 detection using the HEp-2000 sub
Autor:
Dirk Elewaut, C Broddelez, Lai Wang, E M Veys, G. Verbruggen, L. De Ridder, Maria Cornelissen, Karl Almqvist
Publikováno v:
Osteoarthritis and Cartilage. 8(3):170-179
Objective Synthesis rates of aggrecans by phenotypically stable human articular chondrocytes and the immobilization of these aggrecans in large aggregates were used as variables reflecting the capability of these cells of restoring the extracellular